Literature DB >> 12771433

An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response.

Li Dong1, Isamu Mori1, Md Jaber Hossain1, Beixing Liu1, Yoshinobu Kimura1.   

Abstract

The SAM-P1 strain of senescence-accelerated model mice shows an impaired T helper type 1 (Th1) immune response upon infection with influenza virus, which results in high susceptibility to the virus. Treatment of spleen cells from SAM-P1 mice with an immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif (CpG ODN) in vitro increased the ratio of the titre of IFN-gamma to that of IL-4. Administration of CpG ODN to SAM-P1 mice generated satisfactory virus-specific cytotoxic T-lymphocyte responses and natural killer cell activation and the virus-specific immunoglobulin (Ig) isotype switched from IgG1 to IgG2a. Virus growth in the lungs of CpG ODN-treated SAM-P1 mice was cleared quickly and mice survived the lethal influenza virus infection. It could be inferred that a possible mechanism of CpG ODN for normalization of senescence-associated dysregulation of the Th1/Th2 balance involves the upregulated expression of CD154 and CD40 molecules on immune-competent cells. These results suggest that CpG ODN could contribute to the development of a protective strategy against infectious diseases, especially among immunocompromised elderly persons, by stimulating Th1 immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771433     DOI: 10.1099/vir.0.19029-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Characterization of plasmacytoid dendritic cells in bone marrow of pig-tailed macaques.

Authors:  R Keith Reeves; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

Review 2.  Aging and the immune system.

Authors:  Reginald M Gorczynski; Ender Terzioglu
Journal:  Int Urol Nephrol       Date:  2008-08-06       Impact factor: 2.370

3.  Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo.

Authors:  Sven Klaschik; Debra Tross; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2009-01-29       Impact factor: 4.962

4.  Short- and long-term changes in gene expression mediated by the activation of TLR9.

Authors:  Sven Klaschik; Debra Tross; Hidekazu Shirota; Dennis M Klinman
Journal:  Mol Immunol       Date:  2009-12-14       Impact factor: 4.407

5.  Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession.

Authors:  Jian Chen; John Wang; Jun Li; Qi Wu; Fei Chu Lim; Pingar Yang; Hui-Chen Hsu; David T Curiel; John D Mountz
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

6.  Preconditioning with intravenous colitic cell-free DNA prevents DSS-colitis by altering TLR9-associated gene expression profile.

Authors:  Györgyi Műzes; Ferenc Sipos; István Fűri; Miklós Constantinovits; Sándor Spisák; Barnabás Wichmann; Gábor Valcz; Zsolt Tulassay; Béla Molnár
Journal:  Dig Dis Sci       Date:  2014-09-13       Impact factor: 3.199

Review 7.  Antiinfective applications of toll-like receptor 9 agonists.

Authors:  Arthur M Krieg
Journal:  Proc Am Thorac Soc       Date:  2007-07

8.  Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs.

Authors:  M P Alves; L Guzylack-Piriou; V Juillard; J-C Audonnet; T Doel; H Dawson; W T Golde; H Gerber; N Peduto; K C McCullough; A Summerfield
Journal:  Clin Vaccine Immunol       Date:  2009-06-24

9.  Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection.

Authors:  Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant
Journal:  Virol J       Date:  2009-12-02       Impact factor: 4.099

10.  Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Authors:  Elizabeth B Norton; John D Clements; Thomas G Voss; Lucia Cárdenas-Freytag
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.